*Calgary Laboratory Services and University of Calgary
***Division of Urology, University of Calgary, Calgary, AB, Canada
†Charles University, Pilsen, Czech Republic
‡Cruces University Hospital, BioCruces Institute, University of the Basque Country (UPV/EHU), Barakaldo, Bizkaia, Spain
§Carregi Hospital, Florence, Italy
∥Pitié-Salpêtrière Hospital
¶Hopital Cochin, Paris
‡‡Université Lille, Lille, France
#Emory University School of Medicine, Atlanta, GA
**New York University Medical Center, New York, NY
††University of Arkansas for Medical Sciences, Little Rock, AR
§§Barts Cancer Institute, Queen Mary University of London, London, United Kingdom
∥∥AC Camargo Cancer Center, Sao Paulo, Brazil
¶¶Diagnostico Srl Lab Pathology, Montevideo, Uruguay
##Federal University of Bahia, Faculty of Medicine of Bahia, Salvador, Brazil
†††Royal North Shore Hospital, University of Sydney, Sydney, NSW, Australia
‡‡‡Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH
Conflicts of Interest and Source of Funding: Supported in part by Calgary Laboratory Services, Southern Alberta Urology Institute, and Charles University Research Fund (project number P36), by the project CZ.1.05/2.1.00/03.0076 from the European Regional Development Fund and by the project FN 00669806. The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.
Correspondence: Kiril Trpkov, MD, FRCPC, Department of Pathology and Laboratory Medicine, Calgary Laboratory Services and University of Calgary, Rockyview General Hospital, 7007 14 Street, Calgary, AB, Canada T2V 1P9 (e-mail: [email protected]).
